- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03161028
Lipoic Acid for Progressive Multiple Sclerosis (MS) (LAPMS)
January 3, 2024 updated by: VA Office of Research and Development
Lipoic Acid for the Treatment of Progressive Multiple Sclerosis
The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This two-year study will determine if daily oral intake of lipoic acid will prove superior to placebo in reducing injury to the brain and maintaining mobility in progressive MS.
Mobility will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as fall counts.
Neuroprotection will be measured by the extent of brain volume loss seen on MRI.
Study Type
Interventional
Enrollment (Actual)
115
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Ottawa Hospital Research Institute
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20422
- Washington DC VA Medical Center, Washington, DC
-
-
Oregon
-
Portland, Oregon, United States, 97207-2964
- VA Portland Health Care System, Portland, OR
-
-
Texas
-
Dallas, Texas, United States, 75216
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
-
Utah
-
Salt Lake City, Utah, United States, 84148
- VA Salt Lake City Health Care System, Salt Lake City, UT
-
Salt Lake City, Utah, United States, 84148
- University of Utah
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- University of Vermont
-
-
Washington
-
Seattle, Washington, United States, 98108
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
Seattle, Washington, United States, 98122
- Swedish Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of progressive MS as defined by the study
- Able to give informed consent and to adhere to study procedures.
- Expanded Disability Status Scale (EDSS) 3.0 - 6.5: ambulatory for at least 20 meters without rest and use of bilateral aids (canes, crutches, walker) or better.
Exclusion Criteria:
- A self-reported medical or neurological problem other than MS that is a cause of progressive or fluctuating gait dysfunction
- Unable to undergo MRI
- Unable to follow directions in English as standardized scales are not all validated in other languages.
- Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures. Note: Stable abnormal laboratory values of no more than Grade 1 determined to not be of clinical significance to the primary treating physician for that condition may be permitted per local site investigator discretion.
- Pregnant or breast-feeding.
- Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications.
- Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment.
- IV or oral steroids in the 60 days prior to enrolment.
- Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months.
- Participation in the pilot LA in SPMS trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Lipoic Acid
59 subjects receive oral lipoic acid 1200mg daily
|
1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
Other Names:
|
Placebo Comparator: Arm 2: Placebo
59 subjects receive placebo daily
|
The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mobility: Timed 25 Foot Walk
Time Frame: Change in Timed 25 Foot Walk from baseline to year 2
|
Change in Timed 25 Foot Walk from baseline to year 2
|
Change in Timed 25 Foot Walk from baseline to year 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mobility: 2-minute timed walk
Time Frame: Change in 2-minute timed walk from baseline to year 2
|
Change in 2-minute timed walk from baseline to year 2
|
Change in 2-minute timed walk from baseline to year 2
|
Mobility: Fall count
Time Frame: Change in number of falls recorded from baseline to year 2
|
Change in number of falls recorded from baseline to year 2
|
Change in number of falls recorded from baseline to year 2
|
Brain Atrophy by MRI
Time Frame: % change brain volume from baseline to year 2
|
% change brain volume from baseline to year 2
|
% change brain volume from baseline to year 2
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: laboratory safety monitoring, adverse event monitoring
Time Frame: Adverse events and safety labs from baseline to year 2
|
Adverse events and safety labs from baseline to year 2
|
Adverse events and safety labs from baseline to year 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Rebecca I. Spain, MD MSPH, VA Portland Health Care System, Portland, OR
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2018
Primary Completion (Actual)
December 31, 2023
Study Completion (Estimated)
June 30, 2024
Study Registration Dates
First Submitted
May 18, 2017
First Submitted That Met QC Criteria
May 18, 2017
First Posted (Actual)
May 19, 2017
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
January 3, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Disease Attributes
- Chronic Disease
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Vitamin B Complex
- Thioctic Acid
Other Study ID Numbers
- B2682-R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Lipoic acid
-
Rebecca SpainCompletedComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisProgressive Multiple Sclerosis | Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
InVasc Therapeutics, Inc.CompletedHypertension | DiabetesUnited States
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedMultiple SclerosisUnited States
-
Oregon Health and Science UniversityNational Institute on Aging (NIA); National Center for Research Resources (NCRR)CompletedInflammation | Dementia | Oxidative Stress | Hyperlipidemia | Alzheimer's DiseaseUnited States
-
Augusta UniversityXinjiang Medical UniversityCompletedObesity | Cardiovascular Disease | Type 2 DiabetesChina
-
Oregon Health and Science UniversityCompleted
-
Oregon State UniversityOregon Health and Science University; National Center for Complementary and...Active, not recruiting
-
University Health Network, TorontoCanadian Diabetes AssociationCompletedType 2 Diabetes | PrediabetesCanada
-
Khyber Medical University PeshawarActive, not recruitingPeripheral Diabetic NeuropathyPakistan